Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
A drug that powerfully alters GLP-1, GIP, and glucagon signaling could have effects on development that we simply do not understand yet
Human data so far: large trials and meta-analyses have not shown a clear increase in overall cancer, thyroid cancer, or pancreatic cancer , but follow-up is still relatively short for what may become decades-long use
Right now, taking a GLP-1 drug is like hiring someone to come to your house every week and refill your water tank
Lima EBC, Sousa CNS, Meneses LN, Ximenes NC, Santos MA, Vasconcelos GS, Lima NBC, Patrocnio MCA, Macedo D, Vasconcelos SMM (2015) Cocos nucifera (L.) (Arecaceae): a phytochemical and pharmacological review
This graphic highlights just how system-wide their effects really are The Upside (why everyone is paying attention): Metabolic control Insulin secretion Glucagon Glucose uptake (muscle, adipose) Hepatic glucose production Weight loss drivers Gastric emptying earlier satiety Appetite (central nervous system) Lipolysis & thermogenesis Cardiorenal benefits Cardioprotection Diuresis/natriuresis Improved lipid & fatty acid metabolism Potential neurological benefits Signals around neuroprotection, synaptic function, and motor activity The Tradeoffs (often under-discussed): GI tolerability Slowed motility nausea, bloating, constipation Muscle & lean mass considerations Weight loss isnt purely fat risk of lean mass loss without intervention Pancreatic biology Chronic -cell stimulation + remodeling dynamics still being studied System-wide modulation These are not targeted drugs, they actually alter multiple organ systems simultaneously Long-term unknowns Especially around chronic use in non-diabetic, younger populations Any we've missed here
Researchers who are physically active and have low resting heart rates (below 60 beats per minute) may notice the increase more because they are more attuned to their cardiovascular baseline
.jpg)
.png)